Dr. Boorjian on Research With Nadofaragene Firadenovec in Nonmuscle Invasive Bladder Cancer

Partner | Cancer Centers | <b>Mayo Clinic Cancer Center</b>

Stephen A. Boorjian, MD, professor of urology, Mayo Clinic, discusses research with intravesical nadofaragene firadenovec in patients with nonmuscle invasive bladder cancer (NMIBC).

Stephen A. Boorjian, MD, professor of urology, Mayo Clinic, discusses research with intravesical nadofaragene firadenovec in patients with nonmuscle invasive bladder cancer (NMIBC).

In a phase III trial (NCT02773849), investigators evaluated intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive NMIBC. The complete response (CR) rate at any time during therapy in patients with carcinoma in situ served as the primary endpoint of the study, says Boorjian.

Among 103 patients with carcinoma in situ, 55 (53.4%) achieved CR, all by the third month of treatment. Of these 55 patients, 25 (45.5%) remained free of high-grade recurrence at 1 year, demonstrating the durability of these responses, concludes Boorjian.